CBT 400
Alternative Names: CBT-400Latest Information Update: 08 Mar 2024
At a glance
- Originator Creative BioTherapeutics
- Class Eye disorder therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic retinopathy
- Research Macular degeneration
Most Recent Events
- 19 Feb 2024 Early research in Macular degeneration in USA (unspecified route) before February 2024 (Creative BioTherapeutics pipeline, February 2024)
- 19 Feb 2024 Preclinical trials in Diabetic retinopathy in USA (unspecified route) before February 2024 (Creative BioTherapeutics pipeline, February 2024)